Senores Pharmaceuticals Limited — PPTs, 16-05-2025: Investor Presentation

1. Financial Highlights:

Senores Pharmaceuticals posted FY25 total income of INR 410.4 Cr, up 89% YoY, fueled by a 91% revenue increase. EBITDA rose 132% to INR 101.8 Cr, with margins expanding to 24.8% from 19.4%. Profit before tax surged 183% to INR 70.6 Cr, lifting PBT margin to 17.2%. Regulated markets accounted for 60% of sales, growing 69%, while Emerging markets jumped 174%, making up ~30% of revenue. Gross margin improved by 490bps to 56%. Capex reached INR 157.5 Cr with INR 251 Cr planned next year. Working capital efficiency improved through reduced inventory and receivable cycles.

2. Strategic Initiatives & Growth Drivers:

The company is expanding its niche ANDA portfolio in regulated markets, acquiring 15 ANDAs, including government contracts. The CDMO/CMO segment is scaling through new product additions and leveraging USFDA-approved US facilities to mitigate tariff risks. Emerging markets growth is driven by portfolio expansion—48 products registered in Q4, totaling 285. Capex focuses on greenfield API manufacturing and sterile injectable plants in the US.

3. Business Developments:

Senores enhanced its regulated market presence via acquisitions from Dr. Reddy’s and Breckenridge, unlocking government contracts. The CDMO/CMO pipeline grew by 69 products. Emerging markets pipeline expanded with registrations in 40+ countries. Integration of Ratnatris and Havix is advancing, boosting manufacturing in India and the US.

4. Market Position & Competitive Advantage:

Strong R&D capabilities support specialty, niche, and complex product development with substantial CGT exclusivity, the second highest among peers. The company holds 61 approved ANDAs and 22 commercial products, strengthened by USFDA, DEA, and WHO-GMP certifications. Long-term global pharma partnerships ensure steady revenues. Vertical integration from API to finished formulations enhances supply chain control and cost efficiency.

5. Investor Implications:

Senores presents solid growth potential with diverse revenue streams, strong margin expansion, and a scalable CDMO/CMO business. Recent acquisitions and a robust pipeline support sustained momentum. Key risks include US tariff exposure and acquisition integration, but strong regulatory compliance and targeted capex provide a strong base for market share gains and profitability improvement.